ClinicalTrials.gg
RecruitingNCT07793513Updated Nov 12, 2026

Study of BK1803 in Healthy Infants

A Phase 3 interventional study of BK1803 and GOBIK Aqueous Suspension Syringes in Pertussis, Diphtheria and Tetanus, sponsored by Tanabe Pharma Corporation. Recruiting at 33 sites in Japan. Open to participants aged 2 Months to 6 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Tanabe Pharma Corporation · Phase 3, Interventional, and Prevention

How we know

Updated Nov 12, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
344
Allocation
Randomized
Ages
2 Months to 6 Months
Sex
All
01

Study summary

This study is a phase 3, randomized, observer-blinded, active-controlled, multicenter study to evaluate the immunogenicity and safety of BK1803 in healthy infants aged 2 months to less than 7 months.

Participants will be randomized to receive either BK1803 or a control regimen consisting of GOBIK Aqueous Suspension Syringes and Bimmugen® Injection. The primary objective is to demonstrate the noninferiority of BK1803 compared with the control in terms of antibody seroprotection rates against hepatitis B surface (HBs) antigen, Haemophilus influenzae type b (Hib), pertussis, diphtheria, tetanus, and poliovirus. Safety will also be assessed throughout the study.

Read the detailed description

This is a phase 3, randomized, observer-blinded, active-controlled, parallel-group, multicenter study to evaluate the immunogenicity and safety of BK1803 in healthy infants.

BK1803 is a combined vaccine containing antigens against diphtheria, pertussis, tetanus, inactivated poliovirus, Haemophilus influenzae type b (Hib), and hepatitis B. This study aims to assess whether BK1803 provides immunogenicity comparable to standard vaccination regimens.

The study consists of two cohorts: a safety lead-in cohort and a main cohort. In the safety lead-in cohort, participants receive BK1803 to evaluate its initial safety and tolerability before initiating the main cohort. In the main cohort, participants are randomized in a 1:1 ratio to receive either BK1803 or a control regimen consisting of GOBIK Aqueous Suspension Syringes and Bimmugen® Injection.

Participants will receive primary and booster immunizations according to the study schedule, and immunogenicity will be evaluated based on antibody responses to multiple vaccine antigens. Safety will be monitored throughout the study period.

02

Conditions studied

  • Pertussis
  • Diphtheria
  • Tetanus
  • Poliomyelitis
  • Hepatitis B
  • Haemophilus Influenzae Type b

Keywords

  • Hepatitis B
  • Haemophilus influenzae type b
  • Pertussis
  • Diphtheria
  • Tetanus
  • Poliomyelitis
  • Combination Vaccine
  • BK1803
  • Infants
03

In context

Whooping Cough

291 studies on the registry are indexed under Whooping Cough; 24 are open to participants now.

This study's planned enrollment of 344 is below the median of 400 across 229 interventional studies indexed under Whooping Cough.

Browse Whooping Cough studies →

Lead sponsor

Tanabe Pharma Corporation is the lead sponsor of 92 studies on the registry; 1 is open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Months to 6 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects meeting all of the following inclusion criteria at the time of the first vaccination with the study drug will be eligible for study participation.

  1. Japanese healthy infants aged >= 2 months and \< 7 months at the time of the first vaccination with the study drug. However, although subjects meeting the following definition of "subjects who should receive a vaccination with care" may participate in the study, whether or not to enroll them in the study should be decided carefully by the (sub)investigator.
  2. Subjects from whose legal guardians (persons with parental rights) written consent to study participation has been obtained.

Subjects Who Should Receive A Vaccination With Care 4) applies only to the Main Cohort.

  1. Subjects who clearly have underlying diseases, such as cardiovascular disease, kidney disease, liver disease, blood disease, respiratory disease, or a developmental disorder
  2. Subjects who have developed a pyrexia within 2 days after receiving a vaccination in the past
  3. Subjects with a past history of convulsions
  4. (Main Cohort only) Subjects with the gestational age \<37 weeks, or who weighed less than 2500 g at birth

Exclusion criteria

Exclusion Criteria:

Subjects meeting any of the following exclusion criteria at the time of the first vaccination with the study drug will be excluded from study participation. However, (15) applies only to the Safety Lead-in Cohort.

  1. Subjects who have received diagnoses of immunodeficiencies in the past, or who are currently receiving treatments that cause
  2. Subjects with close relatives (up to third degree of kinship) who have a congenital immunodeficiency
  3. Subjects who might experience a serious allergy in response to a food, drug product (especially any component of the study drug), etc.
  4. Subjects who have had Haemophilus Influenzae type b (Hib) infections, pertussis, diphtheria, tetanus, acute poliomyelitis, or in the past
  5. Subjects who have received a vaccination against Hib, pertussis, diphtheria, tetanus, polio, or hepatitis B in the past
  6. Subjects who have received hepatitis B immunoglobulin (HBIG) for the prevention of vertical infection in the past
  7. Subjects who were born to a mother who had received a vaccination against Hib, pertussis, diphtheria, tetanus, polio, or hepatitis B (including a combination vaccine such as diphtheria-pertussis-tetanus vaccine) during pregnancy
  8. Subjects who are receiving anticoagulant therapy or who have thrombocytopenia or coagulation disorder
  9. Subjects with fibrodysplasia ossificans progressiva
  10. Subjects who have received within 27 days before the first vaccination with the study drug
  11. Subjects who have received inactivated vaccines/toxoids or mRNA vaccines within 6 days before the first vaccination with the study drug
  12. Subjects who have received blood transfusions, immunosuppressants (except for topical drugs), or immunoglobulin preparations in the past
  13. Subjects who have received (except for topical drugs) at a prednisolone dose level equivalent of 2 mg/kg/day or higher in the past
  14. Subjects who have participated in another clinical study and received another study drug within 12 weeks before obtaining
  15. (Safety Lead-in Cohort only) Subjects with the gestational age \<37 weeks, or who weighed less than 2500 g at birth
  16. Subjects otherwise judged to be unsuitable for participation in this study by the (sub)investigator
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
344 participants (estimated)

Study arms

  • Experimental
    Safety Lead-in Cohort: BK1803

    Subjects receive BK1803 administered according to the study vaccination schedule, including primary and booster immunizations.

    Biological: BK1803

  • Experimental
    Main Cohort: BK1803

    Subjects receive BK1803 administered according to the study vaccination schedule, including primary and booster immunizations.

    Biological: BK1803

  • Active comparator
    Main Cohort: Control (GOBIK and Bimmugen)

    Subjects receive control vaccines consisting of GOBIK Aqueous Suspension Syringes and Bimmugen® Injection according to the study vaccination schedule, including primary and booster immunizations.

    Biological: GOBIK Aqueous Suspension Syringes · Biological: Bimmugen® Injection

Interventions

  • BiologicalBK1803

    BK1803 is a combination vaccine administered intramuscularly according to the study vaccination schedule, including primary and booster immunizations.

  • BiologicalGOBIK Aqueous Suspension Syringes

    GOBIK Aqueous Suspension Syringes is a combination vaccine administered intramuscularly according to the study vaccination schedule.

  • BiologicalBimmugen® Injection

    Bimmugen® Injection is a hepatitis B vaccine administered subcutaneously according to the study vaccination schedule.

06

What researchers measure

Primary outcomes

  1. Antibody seroprotection rates against vaccine antigens in the BK1803 of Main Cohort

    The antibody seroprotection rates against hepatitis B surface (HBs) antigen, polyribosylribitol phosphate (PRP), Bordetella pertussis (pertussis toxin \[PT\] and filamentous hemagglutinin \[FHA\]), diphtheria toxin, tetanus toxin, and attenuated poliovirus will be evaluated.

    Time frame: 4 weeks from the post-primary immunization of BK1803 in Main Cohort (Visit4)

  2. Antibody seroprotection rates against vaccine antigens for HBs antigen in the Control of Main Cohort

    The antibody seroprotection rates against hepatitis B surface (HBs) antigen will be evaluated.

    Time frame: 4 weeks from the post-booster immunization of Bimmugen in Main Cohort (Visit6)

  3. The antibody seroprotection rates against vaccine antigens for PRP, PT and FHA, diphtheria toxin, tetanus toxin, and attenuated poliovirus in the Control of Main Cohort

    The antibody seroprotection rates against polyribosylribitol phosphate (PRP), Bordetella pertussis (pertussis toxin \[PT\] and filamentous hemagglutinin \[FHA\]), diphtheria toxin, tetanus toxin, and attenuated poliovirus will be evaluated.

    Time frame: 4 weeks from the post-primary immunization of GOBIK in Main Cohort (Visit4)

Secondary outcomes

  1. Geometric mean antibody titers for HBs antigen

    Geometric mean antibody titers against hepatitis B surface (HBs) antigen will be evaluated.

    Time frame: 4 weeks from the post-primary immunization and the post-booster immunization in Safety Lead-in Cohort (Visit 4 and 8); 4 weeks from the post-primary immunization of BK1803 and the post-booster immunization of BK1803/Bimmugen in Main Cohort (Visit 4,6,8)

  2. Geometric mean antibody titers for PRP

    Geometric mean antibody titers against PRP will be evaluated.

    Time frame: 4 weeks from the post-primary immunization and the post-booster immunization in Safety Lead-in Cohort (Visit 4 and 8); 4 weeks from the post-primary immunization and the post-booster immunization of BK1803/GOBIK in Main Cohort (Visit 4 and 8)

  3. Geometric mean antibody titers for Bordetella pertussis (PT and FHA)

    Geometric mean antibody titers against Bordetella pertussis (PT and FHA) will be evaluated.

    Time frame: 4 weeks from the post-primary immunization and the post-booster immunization in Safety Lead-in Cohort (Visit 4 and 8); 4 weeks from the post-primary immunization and the post-booster immunization of BK1803/GOBIK in Main Cohort (Visit 4 and 8)

  4. Geometric mean antibody titers for diphtheria toxin

    Geometric mean antibody titers against diphtheria toxin will be evaluated.

    Time frame: 4 weeks from the post-primary immunization and the post-booster immunization in Safety Lead-in Cohort (Visit 4 and 8); 4 weeks from the post-primary immunization and the post-booster immunization of BK1803/GOBIK in Main Cohort (Visit 4 and 8)

  5. Geometric mean antibody titers for tetanus toxin

    Geometric mean antibody titers against tetanus toxin will be evaluated.

    Time frame: 4 weeks from the post-primary immunization and the post-booster immunization in Safety Lead-in Cohort (Visit 4 and 8); 4 weeks from the post-primary immunization and the post-booster immunization of BK1803/GOBIK in Main Cohort (Visit 4 and 8)

  6. Geometric mean antibody titers for attenuated poliovirus

    Geometric mean antibody titers against attenuated poliovirus will be evaluated.

    Time frame: 4 weeks from the post-primary immunization and the post-booster immunization in Safety Lead-in Cohort (Visit 4 and 8); 4 weeks from the post-primary immunization and the post-booster immunization of BK1803/GOBIK in Main Cohort (Visit 4 and 8)

  7. Antibody seroprotection rates against vaccine antigens

    The antibody seroprotection rates against hepatitis B surface (HBs) antigen, polyribosylribitol phosphate (PRP), Bordetella pertussis (pertussis toxin \[PT\] and filamentous hemagglutinin \[FHA\]), diphtheria toxin, tetanus toxin, and attenuated poliovirus will be evaluated.

    Time frame: 4 weeks from the post-primary and the post-booster of BK1803 in Safety Lead-in Cohort (visit 4and 8); 4 weeks from the post-booster of BK1803/GOBIK in Main Cohort (visit 8)

07

Study locations

33 of 33 sites recruiting
  • Fukui Aiiku Hospital
    Fukui-shi, Fukui 910-0833, Japan
    Recruiting
  • Oda Children's Allergy Clinic
    Fukuoka, Fukuoka 810-0022, Japan
    Recruiting
  • Morooka Chirdren's Chikushi-dori Clinic
    Fukuoka, Fukuoka 812-0894, Japan
    Recruiting
  • Shindo children's clinic
    Fukuoka, Fukuoka 814-0121, Japan
    Recruiting
  • Kurokawa Michiko Pediatric Clinic
    Fukuoka, Fukuoka 815-0033, Japan
    Recruiting
  • Japanese Red Cross Fukuoka Hospital
    Fukuoka, Fukuoka 815-8555, Japan
    Recruiting
  • Isesaki Municipal Hospital
    Isesaki, Gunma 372-0817, Japan
    Recruiting
  • Japanese Red Cross Maebashi Hospital
    Maebashi, Gunma 371-0811, Japan
    Recruiting
  • Yoshimitsu Pediatric Clinic
    Hiroshima, Hiroshima 731-0124, Japan
    Recruiting
  • Taniguchi Children Clinic
    Hiroshima, Hiroshima 732-0023, Japan
    Recruiting
  • Ishikari Kids Clinic
    Ishikari-shi, Hokkaido 061-3202, Japan
    Recruiting
  • Hibarigaoka Kodomo Clinic
    Sapporo, Hokkaido 004-0052, Japan
    Recruiting
  • Araki Children Clinic
    Sapporo, Hokkaido 006-0814, Japan
    Recruiting
  • Japan Community Healthcare Organization Hokkaido Hospital
    Sapporo, Hokkaido 062-8618, Japan
    Recruiting
  • Kumagai Children's Clinic
    Amagasaki, Hyōgo 661-0953, Japan
    Recruiting
  • Hamami Kodomo Clinic
    Chigasaki, Kanagawa 253-0062, Japan
    Recruiting
  • Kawasaki Municipal Hospital
    Kawasaki-shi, Kanagawa 210-0013, Japan
    Recruiting
  • Sagamihara Kyodo Hospital
    Sagamihara, Kanagawa 252-5188, Japan
    Recruiting
  • Kochi Health Sciences Center
    Kochi, Kochi 781-8555, Japan
    Recruiting
  • Sakuranbo Kodomo Clinic
    Kumamoto, Kumamoto 862-0924, Japan
    Recruiting
  • Ina Central Hospital
    Ina-shi, Nagano 396-8555, Japan
    Recruiting
  • JISENKAI Healthcare Incorporated Foundation, Aizawa Hospital
    Matsumoto, Nagano 390-8510, Japan
    Recruiting
  • Arakawa Family Clinic
    Nagano, Nagano 381-0025, Japan
    Recruiting
  • Asama General Hospital
    Saku, Nagano 385-8558, Japan
    Recruiting
  • Nara Prefecture General Medical Center
    Nara, Nara 630-8581, Japan
    Recruiting
  • Aizenbashi Hospital
    Osaka, Osaka 556-0005, Japan
    Recruiting
  • Aiwa Hospital
    Kawagoe-shi, Saitama 350-0001, Japan
    Recruiting
  • Hara Children's Clinic
    Tokorozawa, Saitama 359-1141, Japan
    Recruiting
  • Yaizu City Hospital
    Yaizu, Shizuoka 425-8505, Japan
    Recruiting
  • Medical Corporation Asbo Tokyo Asbo Clinic
    Chuo-ku, Tokyo 104-0031, Japan
    Recruiting
  • Aquakids Clinic
    Edogawa-Ku, Tokyo 133-0056, Japan
    Recruiting
  • Okawa Children & Family Clinic
    Ōta-ku, Tokyo 146-0095, Japan
    Recruiting
  • Karugamo Clinic
    Setagaya-Ku, Tokyo 156-0054, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Apr 2029, 30 months after the start.

Of 27 industry-sponsored phase 3 interventional studies under Whooping Cough, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 22. This study's planned 30 months is above that.

Counting every sponsor, half of 27 studies reached it within 15 months; a quarter within 7 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2026
First posted
Aug 28, 2026
StartActual
Oct 21, 2026
Primary completionEst.
Apr 2029
CompletionEst.
Apr 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
33 sites changed recruiting status (33 now recruiting)
Show 33 sites
  • Fukui Aiiku Hospital · Fukui-shi, Japanno status→Recruiting
  • Oda Children's Allergy Clinic · Fukuoka, Japanno status→Recruiting
  • Morooka Chirdren's Chikushi-dori Clinic · Fukuoka, Japanno status→Recruiting
  • Shindo children's clinic · Fukuoka, Japanno status→Recruiting
  • Kurokawa Michiko Pediatric Clinic · Fukuoka, Japanno status→Recruiting
  • Japanese Red Cross Fukuoka Hospital · Fukuoka, Japanno status→Recruiting
  • Isesaki Municipal Hospital · Isesaki, Japanno status→Recruiting
  • Japanese Red Cross Maebashi Hospital · Maebashi, Japanno status→Recruiting
  • Yoshimitsu Pediatric Clinic · Hiroshima, Japanno status→Recruiting
  • Taniguchi Children Clinic · Hiroshima, Japanno status→Recruiting
  • Ishikari Kids Clinic · Ishikari-shi, Japanno status→Recruiting
  • Hibarigaoka Kodomo Clinic · Sapporo, Japanno status→Recruiting
  • Araki Children Clinic · Sapporo, Japanno status→Recruiting
  • Japan Community Healthcare Organization Hokkaido Hospital · Sapporo, Japanno status→Recruiting
  • Kumagai Children's Clinic · Amagasaki, Japanno status→Recruiting
  • Hamami Kodomo Clinic · Chigasaki, Japanno status→Recruiting
  • Kawasaki Municipal Hospital · Kawasaki-shi, Japanno status→Recruiting
  • Sagamihara Kyodo Hospital · Sagamihara, Japanno status→Recruiting
  • Kochi Health Sciences Center · Kochi, Japanno status→Recruiting
  • Sakuranbo Kodomo Clinic · Kumamoto, Japanno status→Recruiting
  • Ina Central Hospital · Ina-shi, Japanno status→Recruiting
  • JISENKAI Healthcare Incorporated Foundation, Aizawa Hospital · Matsumoto, Japanno status→Recruiting
  • Arakawa Family Clinic · Nagano, Japanno status→Recruiting
  • Asama General Hospital · Saku, Japanno status→Recruiting
  • Nara Prefecture General Medical Center · Nara, Japanno status→Recruiting
  • Aizenbashi Hospital · Osaka, Japanno status→Recruiting
  • Aiwa Hospital · Kawagoe-shi, Japanno status→Recruiting
  • Hara Children's Clinic · Tokorozawa, Japanno status→Recruiting
  • Yaizu City Hospital · Yaizu, Japanno status→Recruiting
  • Medical Corporation Asbo Tokyo Asbo Clinic · Chuo-ku, Japanno status→Recruiting
  • …and 3 more on the registry record
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    33 sites changed recruiting status (33 now recruiting)
    Show 33 sites
    • Fukui Aiiku Hospital · Fukui-shi, Japanno status→Recruiting
    • Oda Children's Allergy Clinic · Fukuoka, Japanno status→Recruiting
    • Morooka Chirdren's Chikushi-dori Clinic · Fukuoka, Japanno status→Recruiting
    • Shindo children's clinic · Fukuoka, Japanno status→Recruiting
    • Kurokawa Michiko Pediatric Clinic · Fukuoka, Japanno status→Recruiting
    • Japanese Red Cross Fukuoka Hospital · Fukuoka, Japanno status→Recruiting
    • Isesaki Municipal Hospital · Isesaki, Japanno status→Recruiting
    • Japanese Red Cross Maebashi Hospital · Maebashi, Japanno status→Recruiting
    • Yoshimitsu Pediatric Clinic · Hiroshima, Japanno status→Recruiting
    • Taniguchi Children Clinic · Hiroshima, Japanno status→Recruiting
    • Ishikari Kids Clinic · Ishikari-shi, Japanno status→Recruiting
    • Hibarigaoka Kodomo Clinic · Sapporo, Japanno status→Recruiting
    • Araki Children Clinic · Sapporo, Japanno status→Recruiting
    • Japan Community Healthcare Organization Hokkaido Hospital · Sapporo, Japanno status→Recruiting
    • Kumagai Children's Clinic · Amagasaki, Japanno status→Recruiting
    • Hamami Kodomo Clinic · Chigasaki, Japanno status→Recruiting
    • Kawasaki Municipal Hospital · Kawasaki-shi, Japanno status→Recruiting
    • Sagamihara Kyodo Hospital · Sagamihara, Japanno status→Recruiting
    • Kochi Health Sciences Center · Kochi, Japanno status→Recruiting
    • Sakuranbo Kodomo Clinic · Kumamoto, Japanno status→Recruiting
    • Ina Central Hospital · Ina-shi, Japanno status→Recruiting
    • JISENKAI Healthcare Incorporated Foundation, Aizawa Hospital · Matsumoto, Japanno status→Recruiting
    • Arakawa Family Clinic · Nagano, Japanno status→Recruiting
    • Asama General Hospital · Saku, Japanno status→Recruiting
    • Nara Prefecture General Medical Center · Nara, Japanno status→Recruiting
    • Aizenbashi Hospital · Osaka, Japanno status→Recruiting
    • Aiwa Hospital · Kawagoe-shi, Japanno status→Recruiting
    • Hara Children's Clinic · Tokorozawa, Japanno status→Recruiting
    • Yaizu City Hospital · Yaizu, Japanno status→Recruiting
    • Medical Corporation Asbo Tokyo Asbo Clinic · Chuo-ku, Japanno status→Recruiting
    • …and 3 more on the registry record
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07793513
Collaborators
The Research Foundation for Microbial Diseases of Osaka University (BIKEN)
Responsible party
Sponsor
First posted
Aug 28, 2026
Start date
Oct 21, 2026
Primary completion
Apr 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Clinical Trials Information Desk
Contact
cti-inq-ml.JP@ml.tanabe-pharma.com
Please email
General Manager
study director · Tanabe Pharma Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion